Meeting
2017 Genitourinary Cancers Symposium
AR nuclear localization and microtubule bundling as markers of docetaxel and cabazitaxel sensitivity in metastatic castration-resistant prostate cancer (mCRPC): Prospective biomarker analysis from TAXYNERGY.
Authors
Paraskevi Giannakakou
Weill Cornell Medicine/Meyer Cancer Center, New York, NY
Paraskevi Giannakakou , Emmanuel S. Antonarakis , Giuseppe Galletti , Daniel Worroll , John Stewart , Atef Zaher , Ted P. Szatrowski , Wei Zhou , Karla V. Ballman , Marie Vanhuyse , Ada Gjyrezi , Shinsuke Tasaki , Yang Bai , Luigi Portella , Brian J. Kirby , Guru Sonpavde , Mario A. Eisenberger , Fred Saad , Scott T. Tagawa , David M. Nanus
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01718353
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 134)
DOI
10.1200/JCO.2017.35.6_suppl.134
Abstract #
134
Poster Bd #
E12
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Emmanuel S. Antonarakis
Poster
2020 Genitourinary Cancers Symposium
Gene expression in circulating tumor cells (CTC) and plasma androgen receptor (AR) gene copy number (CN) for castration-resistant prostate cancer (CRPC) patients (pts) treated with cabazitaxel.
First Author: Giorgia Gurioli
Poster
2016 Genitourinary Cancers Symposium
Interrogating metastatic prostate cancer treatment switch decisions.
First Author: David Lorente
Poster
2015 Genitourinary Cancers Symposium
Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
First Author: Howard I. Scher